A: HERE ARE MY SUGGESTIONS:
- An initial focus on cost considerations and contracting may provide biopharmas with broad access without the need for additional spend on traditional sales and marketing found in commercial populations.
- Consider the potential for more creative contracting solutions potentially based on outcomes in sectors that provide a greater coordination of care or greater cost-consciousness.
- Adopt the moral imperative of treating our most vulnerable and needy populations with the important medicines that they work so hard to bring to market. The willingness and importance of providing affordable access should be at the heart of every company’s mission.
Jeffrey, a 25-year industry veteran, has served in senior executive roles across the healthcare continuum with the likes of Schering-Plough, Merck, the Walgreens Boots Alliance, and UnitedHealth Group.